Novo Nordisk A/S (NOVOb.CO)
968.00DKK
10:59am EDT
kr.-7.00 (-0.72%)
kr.975.00
kr.979.50
kr.985.50
kr.965.00
648,183
689,163
kr.1,100.00
kr.848.00
About
Overall
| Beta: | 0.47 |
| Market Cap (Mil.): | kr.431,450.00 |
| Shares Outstanding (Mil.): | 442.51 |
| Dividend: | 18.00 |
| Yield (%): | 1.85 |
Financials
| NOVOb.CO | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 23.47 | 38.06 | 37.87 |
| EPS (TTM): | 41.55 | -- | -- |
| ROI: | 59.84 | 19.42 | 18.70 |
| ROE: | 68.77 | 20.10 | 19.53 |
India's Sun Pharma gets FDA approval for diabetes generic drug
July 12 - India's Sun Pharmaceutical Industries said on Friday it has received final approval from the United States Food and Drug Administration (FDA) to launch the generic version of Novo Nordisk's Prandin diabetes drug.
Celebrity chef Paula Deen loses more deals, but book sales soar
LOS ANGELES - U.S. celebrity chef Paula Deen saw more lucrative deals evaporate on Thursday despite her renewed apologies for using a racial slur, as retailer Target Corp and drug company Novo Nordisk A/S joined the list of sponsors distancing themselves from the doyenne of Southern cooking.
Celebrity chef Paula Deen loses more deals, but book sales soar
LOS ANGELES, June 27 - U.S. celebrity chef Paula Deen saw more lucrative deals evaporate on Thursday despite her renewed apologies for using a racial slur, as retailer Target Corp and drug company Novo Nordisk A/S joined the list of sponsors distancing themselves from the doyenne of Southern cooking.
RPT-Fitch Affirms 4 STFC's ABS PTCs at 'BBB-sf'; Outlook Stable
June 21 - (The following statement was released by the rating agency)
Denmark's Novo Nordisk says S&P lifts its credit rating
COPENHAGEN, June 19 - Denmark's Novo Nordisk , the world's biggest insulin producer, has had its long-term corporate credit rating raised by Standard & Poor's to "AA-" from "A+", with a stable outlook, the company said.
U.S. court finds Novo Nordisk Prandin diabetes drug patent invalid
- A U.S. appeals court found the patent on Novo Nordisk's Prandin diabetes drug in combination with metformin to be invalid, paving the way for introduction of a generic version of the medicine, the Danish drugmaker said on Tuesday.
US court finds Novo Nordisk Prandin diabetes drug patent invalid
June 18 - A U.S. appeals court found the patent on Novo Nordisk's Prandin diabetes drug in combination with metformin to be invalid, paving the way for introduction of a generic version of the medicine, the Danish drugmaker said on Tuesday.
Novo Nordisk shares hit by concerns over rival diabetes drugs
COPENHAGEN - Novo Nordisk , the world's biggest insulin producer, faces more competition in the diabetes field from rivals Eli Lilly and Sanofi , both of which will showcase new products at an upcoming medical meeting.
UPDATE 1-NORDIC STOCKS - Factors to watch on June 17
HELSINKI, June 17 - The following stocks may be affected by newspaper reports and other factors on Monday:
Novo Nordisk hit by near $1 billion transfer pricing tax claim: TV
COPENHAGEN - Novo Nordisk , the world's biggest insulin producer, is facing a tax claim for 5.5 billion Danish crowns ($975 million) from the Danish authorities in a dispute over transfer pricing, local television broadcaster DR said on Monday.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Plunkett Research, Ltd.
|
$99.00
|
|
Provider: TheStreet.com Ratings
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

